-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by Cantor Fitzgerald
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by Cantor Fitzgerald
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) was downgraded by research analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating in a research note issued on Monday, PriceTargets.com reports.
A number of other research analysts have also issued reports on the company. Raymond James raised ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 target price on the stock in a report on Friday, August 12th. HC Wainwright dropped their price target on ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, August 12th. Finally, StockNews.com raised ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $5.00.
Get ProQR Therapeutics alerts:ProQR Therapeutics Price Performance
Shares of NASDAQ PRQR opened at $0.87 on Monday. ProQR Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $9.09. The firm's 50-day simple moving average is $0.80 and its 200 day simple moving average is $1.14. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.43. The stock has a market cap of $62.02 million, a P/E ratio of -0.87 and a beta of 0.80.
Hedge Funds Weigh In On ProQR Therapeutics
Several large investors have recently made changes to their positions in the company. Monaco Asset Management SAM acquired a new position in ProQR Therapeutics in the first quarter valued at about $82,000. Privium Fund Management B.V. increased its holdings in shares of ProQR Therapeutics by 10.0% in the first quarter. Privium Fund Management B.V. now owns 5,244,446 shares of the biopharmaceutical company's stock worth $4,747,000 after acquiring an additional 478,787 shares in the last quarter. Prosight Management LP increased its holdings in shares of ProQR Therapeutics by 68.0% in the first quarter. Prosight Management LP now owns 599,288 shares of the biopharmaceutical company's stock worth $542,000 after acquiring an additional 242,671 shares in the last quarter. M28 Capital Management LP bought a new stake in shares of ProQR Therapeutics in the first quarter worth about $907,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of ProQR Therapeutics by 14.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,913,394 shares of the biopharmaceutical company's stock worth $31,346,000 after acquiring an additional 481,325 shares in the last quarter.ProQR Therapeutics Company Profile
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
Read More
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Why Apple is Primed to Take a Bite Out of Live Sports
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Home Depot Results Point To Sluggish 2nd Half
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) was downgraded by research analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating in a research note issued on Monday, PriceTargets.com reports.
据PriceTargets.com报道，在周一发布的一份研究报告中，康托·菲茨杰拉德的研究分析师将ProQR治疗公司(纳斯达克：PRQR-GET评级)的评级从“增持”下调至“中性”。
A number of other research analysts have also issued reports on the company. Raymond James raised ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 target price on the stock in a report on Friday, August 12th. HC Wainwright dropped their price target on ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, August 12th. Finally, StockNews.com raised ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $5.00.
其他一些研究分析师也发布了关于该公司的报告。雷蒙德·詹姆斯在8月12日(星期五)的一份报告中将ProQR治疗公司的评级从“市场表现”上调至“跑赢大盘”，并为该股设定了2.00美元的目标价。在5月9日星期一的一份研究报告中，HC Wainwright将他们对ProQR治疗的目标价从4.00美元下调至2.00美元。Chardan Capital在8月12日星期五的一份研究报告中将ProQR治疗公司的评级从“买入”下调至“中性”。最后，StockNews.com在5月9日星期一的一份研究报告中将ProQR治疗公司的评级从“卖出”上调至“持有”。五名研究分析师对该股的评级为持有，四名分析师对该公司股票的评级为买入。根据MarketBeat的数据，该公司的普遍评级为持有，平均目标价为5.00美元。
ProQR Therapeutics Price Performance
ProQR治疗药物性价比
Shares of NASDAQ PRQR opened at $0.87 on Monday. ProQR Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $9.09. The firm's 50-day simple moving average is $0.80 and its 200 day simple moving average is $1.14. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.43. The stock has a market cap of $62.02 million, a P/E ratio of -0.87 and a beta of 0.80.
周一，纳斯达克PRQR的股价开盘报0.87美元。ProQR Treateutics的52周低点为0.53美元，52周高位为9.09美元。该公司的50日简单移动均线切入位为0.80美元，200日简单移动均线切入位为1.14美元。该公司的速动比率为5.93，流动比率为5.93，债务权益比率为0.43。该股市值为6,202万美元，市盈率为-0.87，贝塔系数为0.80。
Hedge Funds Weigh In On ProQR Therapeutics
对冲基金对ProQR治疗公司的看法
ProQR Therapeutics Company Profile
ProQR治疗公司简介
(Get Rating)
(获取评级)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
ProQR Treateutics N.V.是一家生物制药公司，致力于发现和开发基于RNA的治疗遗传疾病的疗法。它主要开发正处于II/III期临床试验的sepofarsen，用于治疗Leber先天性黑发10病的照明试验；以及正在进行II/III期临床试验的ultevursen，用于治疗USH2A介导的视网膜色素变性和USHER综合征。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Why Apple is Primed to Take a Bite Out of Live Sports
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Home Depot Results Point To Sluggish 2nd Half
- 免费获取StockNews.com关于ProQR治疗(PRQR)的研究报告
- 这3只电子游戏股票现在还在玩吗？
- 2辆长期电动汽车的交易价格低于20美元
- 苹果为何准备退出体育直播
- 埃克森美孚和西方石油导致内幕人士本月大量买入
- 家得宝业绩指向低迷的下半年
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ProQR治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ProQR治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧